Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib with reinduction chemotherapy for relapsed or refractory childhood acute lymphoblastic leukemia
NL-OMON23341Phase 2Active, not recruiting
- Sponsor
- Erasmus MC, Rotterdam, Netherlands
- Start
- Sep 2009
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of bortezomib in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Erasmus MC, Rotterdam, Netherlands. Primary endpoint: Antileukemic activity. Started Sep 2009; status: active, not recruiting.
02
Drugs
bortezomib
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on NL-OMON23341.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23341.